Evidence map›Paper›PMID 41289404›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

USP1-TRAF2 axis-regulated mortalin stability mediates chemoresistance by disrupting calcium transport in peripheral T-cell lymphoma.

Ailing Gui, Yichen Yan, Shiyu Jiang, Feng Chen, Xiaolong Zhou, Qi Sun, Shi Qiu, Jichuan Wu, Xiya Li, Junyi Zhang and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ailing Gui *Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.ORCID 0009-0001-1874-5612
Yichen Yan *Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Shiyu Jiang *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Feng ChenDepartment of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Xiaolong ZhouDepartment of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Qi SunDepartment of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Shi QiuDepartment of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Jichuan WuUniversity of Chinese Academy of Sciences Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.
Xiya LiUniversity of Chinese Academy of Sciences Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.
Junyi ZhangDepartment of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Jie LiuDepartment of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Shun ZhuDepartment of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Lan WangUniversity of Chinese Academy of Sciences Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.
Wen LiuDepartment of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Ji ZuoDepartment of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Qunling ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Ling YangDepartment of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.ORCID 0000-0001-9247-637X

Funding

MOST | National Natural Science Foundation of China (NSFC) 81773203MOST | National Natural Science Foundation of China (NSFC) 81970182MOST | National Natural Science Foundation of China (NSFC) 82470189
6 · The paper itself

Abstract

Ubiquitin-specific peptidase 1 (USP1) plays a critical role in the progression and chemoresistance of various cancers, making USP1 inhibitors a promising therapeutic option in cancer treatment. However, the role of USP1 in peripheral T-cell lymphoma (PTCL) has remained unexplored. Our study uncovers a USP1-dependent survival axis driving chemoresistance in PTCL. USP1 is significantly upregulated in PTCL patients and correlates with poor prognosis through promoting mortalin degradation via TRAF2 deubiquitination.

Indexed as

CalciumDrug Resistance, NeoplasmHSP70 Heat-Shock ProteinsLymphoma, T-Cell, PeripheralTNF Receptor-Associated Factor 2Ubiquitin-Specific ProteasesAnimalsApoptosisCell Line, TumorDoxorubicinFemaleGene Expression Regulation, NeoplasticHumansMiceMitochondriaSignal TransductionCalciumDoxorubicinHSP70 Heat-Shock ProteinsTNF Receptor-Associated Factor 2Ubiquitin-Specific ProteasesUSP1 protein, humandoxorubicin resistancemortalinperipheral T-cell lymphomaTRAF2USP1

Identifiers

PMID41289404
PMCPMC12685112

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.